News | August 02, 2011

Feds Support Development of Drugs to Treat Radiation Injury

August 2, 2011 – The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA). Many of the products BARDA is developing may find uses outside emergency medicine, such as treating complications that arise during radiation therapy for cancer.

The contracts are part of an ongoing effort to develop diagnostic tools and drugs to protect health and save lives in a radiological or nuclear emergency such as a nuclear bomb or improvised nuclear device. When the GI tract is exposed to high levels of radiation, it becomes inflamed, and the drugs being studied under these contracts may prevent or decrease that inflammation.

“Radiation injury to the GI tract is highly debilitating and potentially lethal,” said BARDA Director Robin Robinson, M.D. “The early-stage results with these two anti-inflammatory agents are very encouraging, and the additional studies we’re funding will determine whether these drugs have real promise as radiation countermeasures. Our ultimate goal is to develop safe and effective human therapeutics that could be used against acute radiation syndrome.”

Under a two-year, $2 million contract, Apogee Biotechnology Corp. of Hummelstown, Penn., will conduct preliminary studies of a drug known as ABC294640 to evaluate the drug’s efficacy in reducing gastrointestinal injury caused by radiation exposure. The drug works by inhibiting an enzyme called sphingosine kinase. ABC294640 has anti-inflammatory properties and can be taken orally.

The two-year, $2.9 million contract with Avaxia Biologics of Wayland, Mass., supports preliminary efficacy studies for Avaxia’s product, AVX-470. AVX-470 inhibits the effects of a protein called tumor necrosis factor, which increases inflammation. AVX-470 was initially developed to treat inflammatory bowel disease such as Crohn’s disease or ulcerative colitis.

Both contracts fund studies to show if the drugs are effective when administered 24 or more hours after radiation exposure. The studies are the next step in the drug development process and are needed before proceeding to clinical trials and pivotal efficacy studies.

Recognizing that health care providers will need a variety of effective ways to identify and treat the wide range of illnesses and injuries that can be caused by radiological and nuclear incidents, BARDA maintains a robust portfolio of advanced development projects focused on treating radiation-induced bone marrow, lung and skin injuries. BARDA also supports development of medicines to treat radiation-combined injury, in which radiation is combined with burns, blast injury or other trauma. Radiation-combined injury may occur in a nuclear denotation.

BARDA is seeking additional proposals for products that potentially could treat illness and injury from acute radiation syndrome, as well as improved diagnostic tools to measure the radiation dose a person has absorbed after a nuclear detonation or radiation accident. Proposals are accepted through the Broad Agency Announcement BARDA-CBRN-BAA-11-100-SOL-00009 at www.fbo.gov.

BARDA, an agency within the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, provides a comprehensive integrated portfolio approach to the advanced research and development, innovation, acquisition and manufacturing infrastructure for vaccines, drugs, therapeutics, diagnostic tools and non-pharmaceutical products for public health emergency threats. These threats include chemical, biological, radiological and nuclear threats; pandemic influenza; and emerging infectious diseases.

For more information: www.phe.gov

 

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Latest additions to Somatom go. CT platform address advanced clinical fields and applications, including cardiology, CT-guided intervention and dual energy CT. How to lower radiation dose from Computed tomography scanners using ned technology.

Latest additions to Somatom go. CT platform address advanced clinical fields and applications, including cardiology, CT-guided intervention and dual energy CT.

Feature | Computed Tomography (CT) | June 04, 2018 | By Melinda Taschetta-Millane
Recent studies show a rapid increase in patient radiation exposure mainly due to increased use of medical imaging, pa
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
Overlay Init